EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

OC07 | LONG-TERM COMBINATION WITH ONABOTULINUMTOXINA AND ATOGEPANT TO ACHIEVE HIGHER STANDARDS OF MIGRAINE CONTROL: A 52-WEEK, PROSPECTIVE, REAL-WORLD EVALUATION (SYNERGY STUDY)

Confinia Cephalalgica · 03.11.2026 · 36 (s1)

DOI: 10.4081/cc.2026.15945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Confinia Cephalalgica, online erschienen am 03.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with chronic migraine (CM) who remain inadequately controlled despite ongoing preventive monotherapy represent a particularly challenging population. Whether the clinical benefit achieved after adding a second preventive therapy can be maintained over the long term remains poorly understood. Herein, we evaluated the 52-week real-world effectiveness of onabotulinumtoxinA (BoNT-A) plus atogepant in the expanded SYNERGY study.

Methods

We prospectively analyzed 143 adults with CM receiving atogepant added to stable BoNT-A (prior exposure mean 11.8±6.7 months), regardless to prior anti-calcitonin gene-related peptide (CGRP) drugs exposure. Outcomes were assessed at baseline and weeks 12, 24, 36, and 52. Co-primary outcomes were change in monthly migraine days (MMDs) from baseline to week 52 and ≥50% MMDs response (RR50%). Secondary outcomes included monthly headache days (MHDs), acute medication days, HIT-6 and effectiveness using the IHS recommendations at 52 weeks. Sensitive analysis were performed including patients that discontinued treatment. All participants give written informed consent.

Results

Participants were mostly female (134/143, 93.7%, mean age±SD, 41.0±11.3) and 88/143 (61.5%) had prior anti-CGRP monoclonal antibody exposure. Baseline MHDs and MMDs were 22.9 ± 5.7 and 16.6 ± 6.6 days, respectively.At week 52, in the 115 patients completing the follow up, MMDs decreased to 8.2±5.8 days (χ²(4)=199.5, p

Zitieren

APA

(2026). OC07 | LONG-TERM COMBINATION WITH ONABOTULINUMTOXINA AND ATOGEPANT TO ACHIEVE HIGHER STANDARDS OF MIGRAINE CONTROL: A 52-WEEK, PROSPECTIVE, REAL-WORLD EVALUATION (SYNERGY STUDY). Confinia Cephalalgica, 36(s1). https://doi.org/10.4081/cc.2026.15945

Vancouver

OC07 | LONG-TERM COMBINATION WITH ONABOTULINUMTOXINA AND ATOGEPANT TO ACHIEVE HIGHER STANDARDS OF MIGRAINE CONTROL: A 52-WEEK, PROSPECTIVE, REAL-WORLD EVALUATION (SYNERGY STUDY). Confinia Cephalalgica. 2026;36(s1). doi:10.4081/cc.2026.15945

BibTeX
@article{euvimed2026,
  title = {OC07 | LONG-TERM COMBINATION WITH ONABOTULINUMTOXINA AND ATOGEPANT TO ACHIEVE HIGHER STANDARDS OF MIGRAINE CONTROL: A 52-WEEK, PROSPECTIVE, REAL-WORLD EVALUATION (SYNERGY STUDY)},
  journal = {Confinia Cephalalgica},
  year = {2026},
  volume = {36},
  number = {s1},
  doi = {10.4081/cc.2026.15945}
}
Kostenlos starten →